Citations

Clear

6274 citation(s) found for "To, Andrew".

DNMT3A mutations define a unique biological and prognostic subgroup associated with cytotoxic T cells in PTCL-NOS
Herek, Tyler A. , Lone, Waseem , Sharma, Sunandini , Amador, Catalina , Heavican, Tayla B., Qi, Wei , Jochum, Dylan T. , Greiner, Timothy C. , Rosenwald, Andreas , Ott, German , Lim, Soon Thye , Ong, Choon Kiat , Wang, Gang Greg , Staudt, Louis M. , d’Amore, Francesco, Weisenburger, Dennis D. , Chan, Wing C. , Iqbal, Javeed , Bouska, Alyssa , Amador, Catalina , Heavican, Tayla B , Jochum, Dylan , Greiner, Timothy C , Smith, Lynette , Pileri, Stefano , Feldman, Andrew L , Lim, Soon Thye , Ong, Choon Kiat , Jaffe, Elaine S , Wang, Gang Greg , Vose, Julie , d'Amore, Francesco , Iqbal, Javeed , Lone, Waseem G , Li, Yuping , Wei, Qi, Smith, Lynette M. , Pileri, Stefano , Feldman, Andrew L. , Song, Joo Y. , Jaffe, Elaine S. , Rimsza, Lisa M. , Vose, Julie M.

Mayo Clinic

Blood | May 31, 2022 | Volume: 140 | Issue: 11 | Pages: 1278-1290

10.1182/blood.2021015019 | PMID 35639959 Get It

Abstract Peripheral T-cell lymphomas (PTCLs) are heterogenous T-cell neoplasms often associated with epigenetic dysregulation. We investigated de novo DNA methyltransferase 3A (DNMT3A) mutations in common PTCL entities, including angioimmunoblastic T-cell lymphoma and novel molecular subtypes identified within PTCL–not otherwise specified (PTCL-NOS) designated as PTCL-GATA3 and PTCL-TBX21. DNMT3A-mutated PTCL-TBX21 cases showed inferior overall survival (OS), with DNMT3A-mutated residues skewed toward the methyltransferase domain and dimerization motif (S881–R887). Transcriptional profiling demonstrated significant enrichment of activated CD8+ T-cell cytotoxic gene signatures in the DNMT3A-mutant PTCL-TBX21 cases, which was further validated using immunohistochemistry. Genomewide methylation analysis of DNMT3A-mutant vs wild-type (WT) PTCL-TBX21 cases demonstrated hypomethylation in target genes regulating interferon-γ (IFN-γ), T-cell receptor signaling, and EOMES (eomesodermin), a master transcriptional regulator of cytotoxic effector cells. Similar findings were observed in a murine model of PTCL with Dnmt3a loss (in vivo) and further validated in vitro by ectopic expression of DNMT3A mutants (DNMT3A-R882, -Q886, and -V716, vs WT) in CD8+ T-cell line, resulting in T-cell activation and EOMES upregulation. Furthermore, stable, ectopic expression of the DNMT3A mutants in primary CD3+ T-cell cultures resulted in the preferential outgrowth of CD8+ T cells with DNMT3AR882H mutation. Single-cell RNA sequencing(RNA-seq) analysis of CD3+ T cells revealed differential CD8+ T-cell subset polarization, mirroring findings in DNMT3A-mutated PTCL-TBX21 and validating the cytotoxic and T-cell memory transcriptional programs associated with the DNMT3AR882H mutation. Our findings indicate that DNMT3A mutations define a cytotoxic subset in PTCL-TBX21 with prognostic significance and thus may further refine pathological heterogeneity in PTCL-NOS and suggest alternative treatment strategies for this subset.
Long-term follow-up and future direction on the management of chronic lymphocytic leukemia/small lymphocytic leukemia
Hanna, Kirollos S. , Fijalka, Andrew, Ojulu, Apiew, Watson, Ian, Brown, Olivia

Mayo Clinic

Journal of Oncology Pharmacy Practice | May 30, 2022 | Volume: 28 | Issue: 8 | Pages: 1869-1884

10.1177/10781552221103820 | PMID 35635742 Get It

Objective Chronic lymphocytic leukemia and small lymphocytic lymphoma remain the most prevalent adult leukemia in Western countries. Novel therapeutics have established long-term efficacy and have changed the landscape in patient management. In contrast, novel approaches pose opportunities for patients to be treated for finite durations. In this manuscript, we highlight long-term safety and efficacy data with Bruton's tyrosine kinase inhibitors and combination BCL2 + anti-CD20 therapies. We also offer key considerations for treatment selection and outline ongoing trials which may continue to expand therapeutic options and approaches. Data sources An electronic search of the PubMed database was performed to obtain key literature in chronic lymphocytic leukemia and small lymphocytic lymphoma published using the following search terms: chronic lymphocytic leukemia/small lymphocytic lymphoma, Richter syndrome, and histologic transformation. The search results were narrowed by selecting studies in humans published in English. Results were confined to the following article types: Clinical Trial, Phase II; Clinical Trial, Phase III; Clinical Trial, Phase IV; Guideline; Randomized Controlled Trial; Meta-Analysis; Systematic Reviews; and Validation Studies. Data summary Chronic lymphocytic leukemia and small lymphocytic lymphoma are different manifestations of the same disease and are managed in much the same way. Bruton's tyrosine kinase inhibitors have demonstrated long and durable efficacy benefits in patients with newly diagnosed chronic lymphocytic leukemia/small lymphocytic lymphoma and in the relapsed/refractory setting. Despite these benefits, long terms adverse events have posed challenges for patients and have led to treatment discontinuations. Additionally, the use of monotherapy Bruton's tyrosine kinase inhibitor's requires chronic use of the medications leading to added financial implications. BCL2 inhibition with venetoclax in combination with anti-CD20 monoclonal antibodies has offered a novel and finite treatment approach in frontline and relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. Ongoing clinical trials are in investigating this modality further to enhance durable responses utilizing a combination Bruton's tyrosine kinase inhibitor's and BCL2 inhibitors. Conclusion The treatment armamentarium of chronic lymphocytic leukemia/small lymphocytic lymphoma continues to evolve. Despite the long term, durable responses with Bruton's tyrosine kinase inhibitor's, it is likely that finite treatment durations could become the standard of care as a result of continued, long-term responses.
A survey of colonoscopists with and without in‐depth knowledge of water‐aided colonoscopy
Leung, Felix W. , Koo, Malcolm , Yen, Andrew W. , Siau, Keith , Hsieh, Yu‐Hsi , Ishaq, Sauid , Cheng, Chi‐Liang , Ramirez, Francisco C. , Bak, Adrian, Karnes, William E. , Bayupurnama, Putut , Leung, Joseph W., Groen, Piet C. de , Hsieh, Yu-Hsi , Ishaq, Sauid , Cheng, Chi-Liang , Bayupurnama, Putut , Cadoni, Sergio

Mayo Clinic

Journal of Gastroenterology and Hepatology | May 26, 2022 | Volume: 37 | Issue: 9 | Pages: 1785-1791

10.1111/jgh.15896 | PMID 35613903 Get It

AbstractBackground and AimEndoscopy featured water‐aided colonoscopy (WAC) as novel in the Innovation Forum in 2011. Gastrointestinal Endoscopy published a modified Delphi consensus review (MDCR) that supports WAC for clinical practice in 2021. We tested the hypothesis that experience was an important predictor of WAC use, either as water immersion (WI), water exchange (WE), or a combination of WI and WE.MethodsA questionnaire was sent by email to the MDCR authors with an in‐depth knowledge of WAC. They responded and also invited colleagues and trainees without in‐depth knowledge to respond. Logistic regression analysis was used with the reasons for WAC use treated as the primary outcome. Reports related to WAC post MDCR were identified.ResultsOf 100 respondents, > 80% indicated willingness to adopt and modify practice to accommodate WAC. Higher adenoma detection rate (ADR) incentivized WE use. Procedure time slots ≤ 30 and > 30 min significantly predicted WI and WE use, respectively. Co‐authors of the MDCR were significantly more likely to perform WAC (odds ratio [OR] = 7.5, P = 0.037). Unfamiliarity with (OR = 0.11, P = 0.02) and absence of good experience (OR = 0.019, P = 0.002) were associated with colonoscopists less likely to perform WAC. Reports related to WAC post MDCR revealed overall and right colon WE outcomes continued to improve. Network meta‐analyses showed that WE was superior to Cap and Endocuff. On‐demand sedation with WE shortened nursing recovery time.ConclusionsAn important predictor of WAC use was experience. Superior outcomes continued to be reported with WE.
Sport Differences in Fat-Free Mass Index Among a Diverse Sample of NCAA Division III Collegiate Athletes
Brandner, Caleb F. , Luedke, Joel, Erickson, Jacob L. , Harty, Patrick S. , Jagim, Andrew R.

Mayo Clinic

Journal of Strength & Conditioning Research | May 25, 2022 | Volume: 36 | Issue: 8 | Pages: 2212-2217

10.1519/jsc.0000000000004267 | PMID 35612943 Get It

Abstract Brandner, CF, Harty, PS, Luedke, JA, Erickson, JL, and Jagim, AR. Sport differences in fat-free mass index among a diverse sample of NCAA Division III collegiate athletes. J Strength Cond Res 36(8): 2212–2217, 2022—Fat-free mass index (FFMI) is becoming a popular metric to determine an athlete's potential for future fat-free mass accrual or to identify athletes who may be at risk for low fat-free mass (FFM). The aim of the current study was to examine sport-specific differences in FFMI among a cohort of collegiate athletes. NCAA Division III male ( n = 98; age: 20.1 ± 1.6 years, height: 1.82 ± 0.06 m, body mass: 92.7 ± 17.5 kg, %BF: 15.6 ± 8.8%) and female ( n = 92; age: 19.45 ± 1.1 years, height: 1.68 ± 0.06 m, body mass: 65.16 ± 11.04 kg, %BF: 22.71 ± 5.9%) athletes completed a body composition assessment using air displacement plethysmography. Fat-free mass index was calculated by dividing FFM by height squared. The mean ± SD FFMI was significantly higher ( p < 0.05) for males (23.37 ± 2.41 kg·m −2 ) compared with females (17.54 ± 1.8 kg·m −2 ). There was a significant main effect for sport category. Post hoc analysis indicated that throwers had a higher ( p < 0.001) FFMI (mean difference, 95% confidence interval) compared with sprinters and soccer athletes (4.17, 2.03–6.32 kg·m −2 ), endurance and weight-sensitive athletes (4.91, 2.67–7.14 kg·m −2 ), and court sport athletes (4.39, 1.97–6.81 kg·m −2 ), respectively, among female athletes. Post hoc analysis indicated that football players had a higher ( p < 0.01) FFMI than distance runners (3.89, 2.15, 5.62) and wrestlers (2.23, 0.78, 3.68), among male athletes. These findings indicate that sex differences in FFMI exist, with differences identified between sports. These findings can guide strength and nutritional programming decisions by providing sport-specific normative data profiles.
Guiding Kidney Transplantation Candidates for Effective Weight Loss: A Clinical Cohort Study
Kukla, Aleksandra , Diwan, Tayyab S. , Smith, Byron H. , Collazo–Clavell, Maria L. , Lorenz, Elizabeth C. , Clark, Matthew M. , Grothe, Karen, Đenić, Aleksandar , Park, Walter D. , Sahi, Sukhdeep , Issa, Naim , Dean, Patrick G. , Kudva, Yogish C. , Diwan, Tayyab , Amer, Hatem , Issa, Naim , Bentall, Andrew , Mundi, Manpreet S , Stegall, Mark D , Smith, Byron , Denic, Aleksandar , Park, Walter , Schinstock, Carrie A. , Amer, Hatem , Bentall, Andrew , Mundi, Manpreet S. , Stegall, Mark D.

Mayo Clinic

Kidney360 | May 23, 2022 | Volume: 3 | Issue: 8 | Pages: 1411-1416

10.34067/kid.0001682022 | PMID 36176651 Get It

Background Obesity is increasingly common in kidney transplant candidates and may limit access to transplantation. Obesity and diabetes are associated with a high risk for post-transplant complications. The best approach to weight loss to facilitate active transplant listing is unknown, but bariatric surgery is rarely considered due to patient- and physician-related apprehension, among other factors. Methods We aimed to determine the magnitude of weight loss, listing, and transplant rates in 28 candidates with a mean BMI of 44.4±4.6 kg/m 2 and diabetes treated conservatively for 1 year post weight-loss consultations (group 1). Additionally, we evaluated 15 patients (group 2) who met the inclusion criteria but received bariatric intervention within the same time frame. All patients completed a multidisciplinary weight management consultation with at least 1 year of follow-up. Results In the conservatively managed group (group 1), the mean weight at the time of initial consultation was 126.5±18.5 kg, and the mean BMI was 44.4±4.6 kg/m 2 . At 1 year post weight-loss consultation, the mean weight decreased by 4.4±8.2 kg to 122.9±17 kg, and the mean BMI was 43±4.8 kg/m 2 , with a total mean body weight decrease of 3% ( P =0.01). Eighteen patients (64%) did not progress to become candidates for active listing/transplantation during the follow-up time of 4±2.9 years, with 15 (54%) subsequently developing renal failure/diabetes-related comorbidities prohibitive for transplantation. In contrast, mean total body weight decreased by 19% at 6 months post bariatric surgery, and the mean BMI was 34.2±4 and 32.5±3.7 kg/m 2 at 6 and 12 months, respectively. Bariatric surgery was strongly associated with subsequent kidney transplantation (HR=8.39 [95% CI 1.71 to 41.19]; P =0.009). Conclusions A conservative weight-loss approach involving multidisciplinary consultation was ineffective in most kidney transplant candidates with diabetes, suggesting that a more proactive approach is needed.
Inflammatory myofibroblastic tumor: A multi‐institutional study from the Pediatric Surgical Oncology Research Collaborative
Rich, Barrie S. , Fishbein, Joanna , Lautz, Timothy B. , Rubalcava, Nathan S. , Kartal, Tanvi , Newman, Erika, Wok, Pei En, Romao, Rodrigo , Polites, Stephanie F. , Løfberg, Katrine , Lascano, Danny , Davidson, Jacob , Bütter, Andreana , Short, Scott S. , Meyers, Rebecka L. , Mastropolo, Rosemarie, Weller, Jennine , Irfan, Ahmer , Rhee, Daniel S. , Riehle, Kimberly J. , Tracy, Elisabeth T. , Becktell, Kerri, Hallis, Brian, Lal, Dave R. , Li, Orville, Dal‐Soglio, Dorothé B., Piché, Nelson , Quevedo, Oswaldo Gomez, Davidoff, Andrew M. , Barber, Jo Cooke, Watters, Erin, Dasgupta, Roshni , Glick, Richard D. , Lautz, Timothy , Tracy, Elisabeth T , Dasgupta, Roshni , Whitlock, Richard S. , Naik‐Mathuria, Bindi , Kim, Eugene S. , Kastenberg, Zachary J. , Malek, Marcus M. , Utria, Alan Fremder , Rothstein, David H. , Commander, Sarah Jane , Li, Orville, Dal-Soglio, Dorothée, Murphy, Andrew J. , Watters, Erin

Mayo Clinic

International Journal of Cancer | May 23, 2022 | Volume: 151 | Issue: 7 | Pages: 1059-1067

10.1002/ijc.34132 | PMID 35604778 Get It

Abstract Inflammatory myofibroblastic tumor (IMT) is a mesenchymal neoplasm of intermediate malignancy. We describe the largest cohort of IMT patients to date, aiming to further characterize this rare, poorly understood tumor. This is a multi‐institutional review of IMT patients ≤39 years, from 2000 to 2018, at 18 hospitals in the Pediatric Surgical Oncology Research Collaborative. One hundred and eighty‐two patients were identified with median age of 11 years. Thirty‐three percent of tumors were thoracic in origin. Presenting signs/symptoms included pain (29%), respiratory symptoms (25%) and constitutional symptoms (20%). Median tumor size was 3.9 cm. Anaplastic lymphoma kinase (ALK) overexpression was identified in 53% of patients. Seven percent of patients had distant disease at diagnosis. Ninety‐one percent of patients underwent resection: 14% received neoadjuvant treatment and 22% adjuvant treatment. Twelve percent of patients received an ALK inhibitor. Sixty‐six percent of surgical patients had complete resection, with 20% positive microscopic margins and 14% gross residual disease. Approximately 40% had en bloc resection of involved organs. Median follow‐up time was 36 months. Overall 5‐year survival was 95% and 5‐year event‐free survival was 80%. Predictors of recurrence included respiratory symptoms, tumor size and distant disease. Gross or microscopic margins were not associated with recurrence, suggesting that aggressive attempts at resection may not be warranted.
Effect of Intensive versus Standard BP Control on AKI and Subsequent Cardiovascular Outcomes and Mortality: Findings from the SPRINT EHR Study
Drawz, Paul E. , Kaur, Nayanjot , Lenoir, Kristin M. , Suarez, Maritza , Powell, J.R., Raj, Dominic S. , Agarwal, Anil , Soman, Sandeep, Whelton, Paul K. , Rahbari-Oskoui, Frederic F. , Dobre, Mirela , Parkulo, Mark A. , Rocco, Michael V. , McWilliams, Andrew , Dwyer, Jamie P. , Thomas, George , Oparil, Suzanne , Horwitz, Edward , Ishani, Areef , Rai, Nayanjot Kaur , Lenoir, Kristin Macfarlane , Agarwal, Anil K , Dobre, Mirela , Parkulo, Mark A , Rocco, Michael V , McWilliams, Andrew , Dwyer, Jamie P , Oparil, Suzanne , Pajewski, Nicholas M , Ishani, Areef , Drawz, Paul , Rahbari-Oskoui, Frederic F , Powell, James R., Beddhu, Srinivasan , Lash, James P. , Rahman, Mahboob , Pajewski, Nicholas M.

Mayo Clinic

Kidney360 | May 23, 2022 | Volume: 3 | Issue: 7 | Pages: 1253-1262

10.34067/kid.0001572022 | PMID 35919535 Get It

Key Points Identifying ways to prevent AKI may reduce mortality further in the setting of intensive BP control. Creatinine-based ascertainment of AKI, enabled by electronic health record data, may be more sensitive and less biased than traditional serious adverse event adjudication. Background Adjudication of inpatient AKI in the Systolic Blood Pressure Intervention Trial (SPRINT) was based on billing codes and admission and discharge notes. The purpose of this study was to evaluate the effect of intensive versus standard BP control on creatinine-based inpatient and outpatient AKI, and whether AKI was associated with cardiovascular disease (CVD) and mortality. Methods We linked electronic health record (EHR) data from 47 clinic sites with trial data to enable creatinine-based adjudication of AKI. Cox regression was used to evaluate the effect of intensive BP control on the incidence of AKI, and the relationship between incident AKI and CVD and all-cause mortality. Results A total of 3644 participants had linked EHR data. A greater number of inpatient AKI events were identified using EHR data (187 on intensive versus 155 on standard treatment) as compared with serious adverse event (SAE) adjudication in the trial (95 on intensive versus 61 on standard treatment). Intensive treatment increased risk for SPRINT-adjudicated inpatient AKI (HR, 1.51; 95% CI, 1.09 to 2.08) and for creatinine-based outpatient AKI (HR, 1.40; 95% CI, 1.15 to 1.70), but not for creatinine-based inpatient AKI (HR, 1.20; 95% CI, 0.97 to 1.48). Irrespective of the definition (SAE or creatinine based), AKI was associated with increased risk for all-cause mortality, but only creatinine-based inpatient AKI was associated with increased risk for CVD. Conclusions Creatinine-based ascertainment of AKI, enabled by EHR data, may be more sensitive and less biased than traditional SAE adjudication. Identifying ways to prevent AKI may reduce mortality further in the setting of intensive BP control.
COVLIAS 1.0Lesion vs. MedSeg: An Artificial Intelligence Framework for Automated Lesion Segmentation in COVID-19 Lung Computed Tomography Scans
Suri, Jasjit S. , Agarwal, Sushant , Chabert, Gian Luca , Carriero, Alessandro , Paschè, Alessio , Saba, Luca , Mehmedović, Armin , Faa, Gavino , Singh, Inder M. , Turk, Monika, Chadha, Paramjit S., Johri, Amer M. , Khanna, Narendra N. , Laird, John R. , Pareek, Gyan , Miner, Martin , Sobel, David , Balestrieri, Antonella , Sfikakis, Petros P. , Tsoulfas, George, Protogerou, Athanase D. , Misra, Durga Prasanna , Agarwal, Vikas , Teji, Jagjit S. , Al-Maini, Mustafa , Dhanjil, Surinder, Rathore, Vijay , Fatemi, Mostafa , Krishnan, Pudukode R., Nagy, F. , Fouda, Mostafa M. , Naidu, Subbaram, Višković, Klaudija , Kalra, Manudeep, Mehmedović, Armin , Faa, Gavino , Sobel, David W , Tsoulfas, George , Protogerou, Athanasios , Agarwal, Vikas , Fatemi, Mostafa , Alizad, Azra , Ferenc, Nagy , Fouda, Mostafa M , Naidu, Subbaram , Viskovic, Klaudija , Misra, Durga Prasanna , Agarwal, Sushant , Suri, Jasjit S. , Danna, Pietro , Saba, Luca , Mavrogeni, Sophie , Kitas, George D. , Nicolaides, Andrew , Sharma, Aditya , Alizad, Azra , Ruzsa, Zoltán

Mayo Clinic

Diagnostics | May 21, 2022 | Volume: 12 | Issue: 5 | Pages: 1283

10.3390/diagnostics12051283 | PMID 35626438 Get It

Background: COVID-19 is a disease with multiple variants, and is quickly spreading throughout the world. It is crucial to identify patients who are suspected of having COVID-19 early, because the vaccine is not readily available in certain parts of the world. Methodology: Lung computed tomography (CT) imaging can be used to diagnose COVID-19 as an alternative to the RT-PCR test in some cases. The occurrence of ground-glass opacities in the lung region is a characteristic of COVID-19 in chest CT scans, and these are daunting to locate and segment manually. The proposed study consists of a combination of solo deep learning (DL) and hybrid DL (HDL) models to tackle the lesion location and segmentation more quickly. One DL and four HDL models—namely, PSPNet, VGG-SegNet, ResNet-SegNet, VGG-UNet, and ResNet-UNet—were trained by an expert radiologist. The training scheme adopted a fivefold cross-validation strategy on a cohort of 3000 images selected from a set of 40 COVID-19-positive individuals. Results: The proposed variability study uses tracings from two trained radiologists as part of the validation. Five artificial intelligence (AI) models were benchmarked against MedSeg. The best AI model, ResNet-UNet, was superior to MedSeg by 9% and 15% for Dice and Jaccard, respectively, when compared against MD 1, and by 4% and 8%, respectively, when compared against MD 2. Statistical tests—namely, the Mann–Whitney test, paired t-test, and Wilcoxon test—demonstrated its stability and reliability, with p < 0.0001. The online system for each slice was <1 s. Conclusions: The AI models reliably located and segmented COVID-19 lesions in CT scans. The COVLIAS 1.0Lesion lesion locator passed the intervariability test.
Durability analysis of the highly effective mRNA-1273 vaccine against COVID-19
Puranik, Arjun, O’Horo, John C. , Pawlowski, Colin , Virk, Abinash , Kremers, Walter K. , Breeher, Laura E. , Gordon, Joel , Geyer, Holly L. , Speicher, Leigh L. , Challener, Doug W, Breeher, Laura, Gordon, Joel E, Speicher, Leigh Lewis, O'Horo, John C , Kremers, Walter K , Lenehan, Patrick J. , Swift, Melanie D. , Venkatakrishnan, A J , Challener, Douglas W. , Breeher, Laura , Soundararajan, Venky , Badley, Andrew D.

Mayo Clinic

PNAS Nexus | May 21, 2022 | Volume: 1 | Issue: 2 | Pages: No page available

10.1093/pnasnexus/pgac058 | PMID 36713311 Get It

Abstract COVID-19 vaccines are effective, but breakthrough infections have been increasingly reported. We conducted a test-negative case-control study to assess the durability of protection against symptomatic infection after vaccination with mRNA-1273. We fit conditional logistic regression (CLR) models stratified on residential county and calendar date of SARS-CoV-2 PCR testing to assess the association between the time elapsed since vaccination and the odds of symptomatic infection, adjusted for several covariates. There were 2,364 symptomatic individuals who had a positive SARS-CoV-2 PCR test after full vaccination with mRNA-1273 (“cases”) and 12,949 symptomatic individuals who contributed 15,087 negative tests after full vaccination (“controls”). The odds of symptomatic infection were significantly higher 250 days after full vaccination compared to the date of full vaccination (Odds Ratio [OR]: 2.47, 95% confidence interval [CI]: 1.19–5.13). The odds of non-COVID-19 associated hospitalization and non-COVID-19 pneumonia (negative control outcomes) remained relatively stable over the same time interval (Day 250 ORNon-COVID Hospitalization: 0.68, 95% CI: 0.47–1.0; Day 250 ORNon-COVID Pneumonia: 1.11, 95% CI: 0.24–5.2). The odds of symptomatic infection remained significantly lower almost 300 days after the first mRNA-1273 dose as compared to 4 days after the first dose, when immune protection approximates the unvaccinated state (OR: 0.26, 95% CI: 0.17–0.39). Low rates of COVID-19 associated hospitalization or death in this cohort precluded analyses of these severe outcomes. In summary, mRNA-1273 robustly protected against symptomatic SARS-CoV-2 infection at least 8 months after full vaccination, but the degree of protection waned over this time period.